Vectura’s portfolio has emerged from the Company’s product development, formulation and drug delivery expertise and is currently centred around developing inhaled products to address unmet needs in airways diseases.

We continue to focus on balancing the unmet needs of all stakeholders (patients, physicians, payors) with commercial attractiveness and exploiting valuable niches in our therapeutic space.

   Investors

Date: 05/02/2016

Share price summary

1

WE INNOVATE

2

WE DEVELOP

3

WE COLLABORATE

Annual report

AR-15.png

Download annual report

Presentations and webcasts

23-24 February 2016

RBC Capital Markets Global Healthcare Conference, New York

11-14 January 2016

J.P. Morgan Annual Healthcare Conference, San Francisco.
Vectura - CEO presentation 16:30 PST/00:30 GMT (13 Jan)

18 November 2015

Business Review Webinar - 'Developing the next generation of inhaled products'

View full list